Antibodies News and Research

RSS

The case for vaccinating children under 12 against COVID-19

Researchers assess the need for coronavirus disease 2019 (COVID-19) vaccination in children who are 12 years of age or younger.

14 Nov 2021

Increased risk of breakthrough SARS-CoV-2 infection with ChAdOx1 compared to BNT162b2 vaccine

Researchers study individuals recruited in the ‘Virus Watch’ community cohort who had received their second dose of either ChAdOx1 or BNT162b2 vaccine.

14 Nov 2021

Partial resistance to neutralizing antibodies and enhanced transmissibility of SARS-CoV-2 Delta variant

A new study estimates the efficacy of the immune response induced by vaccination and natural COVID-19 infection against the Kappa and Delta lineages.

14 Nov 2021

Study assesses whether medicinal mushrooms and Chinese herbs can help treat COVID-19

A novel study is assessing whether medicinal mushrooms and Chinese herbs provide therapeutic benefit in treating acute COVID-19 infection.

12 Nov 2021

NanoTCE technology shows promise for treatment of acute myeloid leukemia

Oncotarget published "Nanoparticle T cell engagers for the treatment of acute myeloid leukemia" which reported that Acute myeloid leukemia (AML) is the most common type of leukemia and has a 5-year survival rate of 25%.

12 Nov 2021

New findings about naturally acquired immunity may help improve existing malaria vaccines

When you have become immune to malaria after having contracted the disease, it seems that the body uses a more efficient protection than if you have been vaccinated against the deadly disease.

12 Nov 2021

Higher order protein catenation leads to the development of artificial antibodies

Chemical topology is a unique dimension for protein engineering. Over the past few years, the discovery of topological nontrivial proteins in nature has already revealed their many potential functional benefits, such as enhanced thermal/mechanical/chemical stability.

12 Nov 2021

COVID-19 vaccination humoral immune response in individuals with diabetes

A new study investigated the humoral immune response and side effects related to COVID-19 vaccines in individuals with type 1 diabetes and type 2 diabetes.

12 Nov 2021

Immune responses with and without previous SARS-CoV-2 infection following single BNT162b2 vaccine dose

The Protective Immunity from T-cells to COVID-19 in Healthcare workers (PITCH) is a prospective, cohort, multi-center study enclosed within the SIREN study designed to assess the effectiveness of the BNT162b2 vaccine in healthcare workers.

12 Nov 2021

Impact of mutations on binding affinity of SARS-CoV-2 variants with ACE2 and existing antibodies

Researchers explained their analysis of the mechanisms that trigger the docking of SARS-CoV-2 variants to ACE2 and the antibodies, referred to as protein-protein docking.

12 Nov 2021

Study investigates the degree of Covid-19 vaccination protection in dialysis patients

Researchers led by the Marien Hospital Herne, a Ruhr-Universität Bochum clinic, have investigated the extent to which mRNA vaccines protect dialysis patients from infection with variants of concerns of Sars-Cov-2.

12 Nov 2021

Analysis of immunodeficient patients granted REGEN-COV under compassionate use COVID-19 program

A team of scientists describe the safety and response to REGEN-COV® for COVID-19 patients with immunodeficiency-associated antibody disorders.

11 Nov 2021

Long-lasting anti-spike and anti-membrane antibodies can differentiate between COVID-19 infection and vaccination

Researchers have been investigating which other proteins remain prevalent long enough for tests against them to be worthwhile.

11 Nov 2021

New Delta sublineage shows no additional resistance to neutralization

Researchers are attempting to determine the ability of this new sublineage to avoid neutralization by antibodies elicited from vaccination.

11 Nov 2021

Immunity following COVID-19 vaccination and natural infection in India

The researchers evaluated immune response markers in a cross-section of people from the Indian state of West Bengal, including those vaccinated with either Covishield or Covaxin, the unvaccinated cohort, and the naturally infected.

11 Nov 2021

Phage-like particle system provides a platform for quick and easy vaccine generation

In this study, researchers report on the development of a monovalent lambda PLP-based vaccine against SARS-CoV-2 or MERS-Cov through decoration with the spike RBD proteins from either virus.

11 Nov 2021

REGEN-COV shown to rapidly reduce SARS-CoV-2 viral load in hospitalized COVID-19 patients

Studies have shown that mortality rates in hospitalized patients with COVID-19 are high, ranging between 10% and 30%. REGEN-COV®, a combination of monoclonal antibodies casirivimab and imdevimab, is approved in the United States and other regions for emergency treatment of COVID-19 outpatients with mild to moderate SARS-CoV-2 infection and post-exposure prophylaxis.

10 Nov 2021

Evidence that mild and even asymptomatic SARS-CoV-2 infection can lead to sustained immune activation

A paper published in the open-access journal Viruses, reports on a study investigating long-term changes to soluble inflammatory factors and cellular immune phenotype and function in 22 survivors of mild SARS-CoV-2 infection. The observations were then compared to 11 individuals who had recovered from other mild respiratory infections.

10 Nov 2021

New discovery could lead to the creation of a pan-coronaviruses vaccine

Next generation vaccines for Covid-19 should aim to induce an immune response against 'replication proteins', essential for the very earliest stages of the viral cycle, concludes new research carried out by UCL scientists.

10 Nov 2021

First detection of SARS-CoV-2 remdesivir resistance in an immunocompromised patient

A research group from the US (led by experts from Yale University School of Medicine) recently presented a case of an immunocompromised female patient with acquired deficiency of B lymphocytes who subsequently developed a protracted course of the infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

10 Nov 2021

Antibodies News and Research

The case for vaccinating children under 12 against COVID-19

Increased risk of breakthrough SARS-CoV-2 infection with ChAdOx1 compared to BNT162b2 vaccine

Partial resistance to neutralizing antibodies and enhanced transmissibility of SARS-CoV-2 Delta variant

Study assesses whether medicinal mushrooms and Chinese herbs can help treat COVID-19

NanoTCE technology shows promise for treatment of acute myeloid leukemia

New findings about naturally acquired immunity may help improve existing malaria vaccines

Higher order protein catenation leads to the development of artificial antibodies

COVID-19 vaccination humoral immune response in individuals with diabetes

Immune responses with and without previous SARS-CoV-2 infection following single BNT162b2 vaccine dose

Impact of mutations on binding affinity of SARS-CoV-2 variants with ACE2 and existing antibodies

Study investigates the degree of Covid-19 vaccination protection in dialysis patients

Analysis of immunodeficient patients granted REGEN-COV under compassionate use COVID-19 program

Long-lasting anti-spike and anti-membrane antibodies can differentiate between COVID-19 infection and vaccination

New Delta sublineage shows no additional resistance to neutralization

Immunity following COVID-19 vaccination and natural infection in India

Phage-like particle system provides a platform for quick and easy vaccine generation

REGEN-COV shown to rapidly reduce SARS-CoV-2 viral load in hospitalized COVID-19 patients

Evidence that mild and even asymptomatic SARS-CoV-2 infection can lead to sustained immune activation

New discovery could lead to the creation of a pan-coronaviruses vaccine

First detection of SARS-CoV-2 remdesivir resistance in an immunocompromised patient

Immunology eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News